Potent, selective benzenesulfonamide agonists of the human β3 adrenergic receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 9, 1998, Pages 1101-1106

  Weber, Ann E ^a   Mathvink, Robert J ^a   Perkins, Leroy ^a   Hutchins, Jennifer E ^a   Candelore, Mari R ^a   Tota, Laurie ^a   Strader, Catherine D ^a,b   Wyvratt, Matthew J ^a   Fisher, Michael H ^a  

^a Biostatist and Res Data Systems   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR;

ACYLATION; ALKYLATION; ARTICLE; BETA ADRENERGIC STIMULATION; BINDING AFFINITY; DRUG SYNTHESIS; LIPOLYSIS; OBESITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TECHNIQUE;

ADRENERGIC BETA-AGONISTS; CLONING, MOLECULAR; DRUG DESIGN; HUMANS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0032080782     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00169-3     Document Type: Article

References (32)

1. 2. For recent reviews see: a) Lowell, B. B.; Flier, J. S. Annu. Rev. Med. 1997, 48, 307-316;
2. b) Arch, J. R. S.; Wilson, S. Int. J. Obesity 1996, 20, 191-199;
3. c) Himms-Hagen, J.; Danforth, E. Curr. Opin. Endocrin. Diabetes 1996, 3, 59-65;
4. d) Claus, T. H.; Bloom, J. D. Ann. Rep. Med. Chem. 1995, 30, 189-198;
5. e) Howe, R. Drugs Fut. 1993, 18, 529-549;
6. f) Arch, J. R. S.; Kaumann, A. J. Med. Res. Rev., 1993, 13, 663-729.
7. 3. Arch, J. R. S.; Ainsworth, A. T.; Cawthorne, M. A.; Piercy, V.; Sennitt, M. V.; Thody V. E.; Wilson, C.; Wilson, S. Nature 1984, 309, 163-165
8. 4. Bloom, J. D.; Dutia, M. D.; Johnson, B. D.; Wissner, A.; Burns, M. G.; Largis, E. E.; Dolan, J. A.; Claus, T. H. J. Med. Chem. 1992, 35, 3081-3084.
9. 5. Meier, M. K.; Alig, L.; Burf-Saville, M. E. Int. J. Obesity 1984, 8(Suppl.1), 215-225.
10. 6 . Howe, R.; Rao, B. S.; Holloway, B. R.; Stribling, D. J. Med. Chem. 1992, 35, 1751-1759.
11. 7. Howe, R.; Rao, B. S.; Holloway, B. R.; Stribling, D. J. Med. Chem. 1992, 35, 1759-1764.
12. 8. Connacher, A. A.; Jung, R. T.; Mitchell, P. E. G. Brit. Med. J. 1988, 296, 1217-1220.
13. 9. Cawthorne, M. A.; Sennitt, M. V.; Arch, J. R. S.; Smith, S. A. Amer. J. Clin. Nutr. 1992, 55, 252S-257S.
14. 10. Henny, C.; Buckert, A.; Schutz, T.; Jequier, E.; Felber, J.-P.; Int. J. Obesity 1988, 12, 227-236.
15. 11. Granneman, J. G.; Lahners, K. N.; Chaudhry, A. Mol. Pharmacol. 1991, 40, 895-899.
16. 12. Muzzin, P.; Reveilli, J.-P.; Kuhne, F.; Gocayne, J. D.; McCombie, W. R.; Venter, J. C.; Giacobino, J.-P.; Fraser, C. M. J. Biol. Chem. 1991, 266, 24053-24058.
17. 13. Emorine, L. J.; Marullo, S.; Briend-Sutren, M-M.; Patey, G.; Tate, K.; Delavier-Klutchko, C.; Strosberg, A. D. Science 1989, 245, 1118-1121.
18. 14. Granneman, J. G.; Lahners, K. N.; Rao, D. D. Mol. Pharmacol. 1992, 42, 964-970.
19. 15. Liggett, S. B. Mol. Pharmacol. 1992, 42, 634-637.
20. 16. Beeley, L. J.; Berge, J. M.; Chapman, H.; Dean, D. K.; Kelly, J.; Lowden, K.; Kotecha, N. R.; Morgan, H. K. A.; Rami, H. K.; Thompson, M.; Vong, A. K. K.; Ward, R. W. Bioorg. Med. Chem. Lett. 1997, 7, 219-224.
21. 17. Sher, P. M.; Mathur, A.; Fisher, L. G.; Wu, G.; Skwish, S.; Michel, I. M.; Seiler, S. M.; Dickinson, K. E. J. Bioorg. Med. Chem. Lett. 1997, 7, 1583-1588.
22. 18. Fisher, L. G.; Sher P. M.; Skwish, S.; Michel, I. M.; Seiler, S. M.; Dickinson, K. E. J. Bioorg. Med. Chem. Lett. 1997, 7, 2253-2258.
23. 125I-iodocyanopindolol binding, repectively.
24. 125I-iodocyanopindolol binding, repectively.
25. 20. Lönnqvist, F.; Krief, S.; Strosberg, A. D.; Nyberg, B.; Emorine, L. J.; Arner, P. Br. J. Pharm. 1993, 110, 929-936.
26. 21. This route is a modification of that reported for the asymmetric synthesis of propranolol: Klunder, J. M.; Ko, S. Y.; Sharpless, K. B. J. Org. Chem. 1986, 51, 3710-3712.
27. 22. All final compounds were characterized by NMR, mass spectrometry, and HPLC.
28. 23. Prepared via reductive alkylation of (S)-α-methylbenzylamine with 4'-methoxyphenyl-2-butanone according to the procedure outlined in Clifton, J. E.; Collins, I.; Hallett, P.; Hartley, D.; Lunts, L. H. C.; Wicks, P. D. J. Med. Chem. 1982, 25, 670-679.
29. 24. For experimental details see: Fisher, M. H.; Mathvink, R. J.; Ok, H.O.; Parmee, E. R.; Weber, A. E. U. S. Patent 5 451 677, 1995; Chem. Abstr. 1996, 724, 116877.
30. 24. For experimental details see: Fisher, M. H.; Mathvink, R. J.; Ok, H.O.; Parmee, E. R.; Weber, A. E. U. S. Patent 5 451 677, 1995; Chem. Abstr. 1996, 724, 116877.
31. 25. Candelore, M. R., unpublished results.
32. 26. Wilson, S.; Chambers, J. K.; Park, J. E.; Ladurner, A.; Cronk, D. W.; Chapman, C. G.; Kallender, H.; Browne, M. J.; Murphy, G. J.; Young, P. W. J. Pharm. Exper. Ther. 1996, 279, 214-221.